Skip to content
lifestyle.d-h.st
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Cumulus Neuroscience
NeuLogiq® Platform Helps Confirm No Evidence of Psychotomimetic, Hallucinatory, or Dissociative Effects in a Phase 1b Study of a Novel Neuroplastogen Developed for Major Depressive Disorder
May 28, 2026
Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Customer Shionogi & Co., Ltd.
February 12, 2026
Cumulus Neuroscience Appoints Ricardo Sáinz Fuertes, MD as New Board Chair
January 8, 2026
Cumulus Neuroscience Publishes Data Validating a Scalable Measurement of Neuroplasticity Using Low-Burden Dry Sensor EEG
January 6, 2026